The European Medicines Agency has qualified the first artificial intelligence-based tool designed to evaluate liver biopsies in patients with metabolic dysfunction-associated steatohepatitis (MASH). The system, called AIM-NASH, helps pathologists assess disease severity and reduce variability in histological scoring, with the aim of accelerating drug development for this increasingly common liver condition.
The Cystic Fibrosis Foundation has committed up to US$2.3 million (about £1.7 million) in equity investment to Owlstone Medical for the development of a breath test to detect Pseudomonas aeruginosa (PA) infections in people with cystic fibrosis (CF). The Cambridge-based company announced the investment on March 25, 2025, marking a significant step forward in respiratory […]
Researchers have developed a simple, robust blood test that accurately measures type 1 diabetes-related autoimmunity using minimal blood volumes, making it particularly suitable for paediatric patients. Called BASTA (β cell antigen-specific T cell assay), this test captures CD4+ T cell responses to pancreatic beta cells, offering an improved method to track autoimmune responses in both […]
Diagnostic technology company Owlstone Medical has raised $27 million (£22m) in Series E financing to advance its breath-based testing platform for early disease detection, with particular focus on lung cancer, liver disease, and digestive disorders.
Researchers have developed a highly accurate blood test for amyotrophic lateral sclerosis (ALS), potentially reducing diagnosis times and improving patient outcomes.
April 2024
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.